- Home
- ISRL vs FBIOP Comparison
ISRL vs FBIOP Comparison
Compare ISRL & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- FBIOP
- Stock Information
- Founded
- ISRL 2021
- FBIOP N/A
- Country
- ISRL United States
- FBIOP United States
- Employees
- ISRL N/A
- FBIOP 101
- Industry
- ISRL Blank Checks
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- FBIOP Health Care
- Exchange
- ISRL Nasdaq
- FBIOP Nasdaq
- Market Cap
- ISRL 80.0M
- FBIOP N/A
- IPO Year
- ISRL 2023
- FBIOP N/A
- Fundamental
- Price
- ISRL $12.50
- FBIOP $7.89
- Analyst Decision
- ISRL
- FBIOP
- Analyst Count
- ISRL 0
- FBIOP 0
- Target Price
- ISRL N/A
- FBIOP N/A
- AVG Volume (30 Days)
- ISRL 19.9K
- FBIOP N/A
- Earning Date
- ISRL 01-01-0001
- FBIOP N/A
- Dividend Yield
- ISRL N/A
- FBIOP N/A
- EPS Growth
- ISRL N/A
- FBIOP N/A
- EPS
- ISRL 0.20
- FBIOP N/A
- Revenue
- ISRL N/A
- FBIOP N/A
- Revenue This Year
- ISRL N/A
- FBIOP N/A
- Revenue Next Year
- ISRL N/A
- FBIOP N/A
- P/E Ratio
- ISRL $62.11
- FBIOP N/A
- Revenue Growth
- ISRL N/A
- FBIOP N/A
- 52 Week Low
- ISRL $11.00
- FBIOP N/A
- 52 Week High
- ISRL $14.00
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- ISRL 47.41
- FBIOP 49.79
- Support Level
- ISRL $12.53
- FBIOP $7.37
- Resistance Level
- ISRL $12.99
- FBIOP $8.40
- Average True Range (ATR)
- ISRL 0.61
- FBIOP 0.63
- MACD
- ISRL -0.04
- FBIOP -0.12
- Stochastic Oscillator
- ISRL 11.95
- FBIOP 37.80
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.